Related Experiment Videos
Epstein-Barr virus in patients with immunodeficiency disorders
1Department of Pediatrics, Hokkaido University School of Medicine, Sapporo, Japan. moto-oka@med.hokudai.ac.jp
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie
|October 24, 2001
Summary
Epstein-Barr virus (EBV) can cause serious diseases, especially in immunocompromised individuals. EBV-associated lymphoproliferative disorders range from benign to malignant, with severe outcomes possible in certain immunodeficiencies.
Area of Science:
- Virology
- Immunology
- Oncology
Background:
- Epstein-Barr virus (EBV) is a human herpesvirus linked to various diseases.
- EBV infections are increasingly reported in patients with primary or acquired immunodeficiencies.
- Immunocompromised states alter the typical course of EBV infections.
Purpose of the Study:
- To review the spectrum of EBV-associated diseases in immunocompromised individuals.
- To highlight the clinical manifestations and outcomes of EBV in specific immunodeficient settings.
- To emphasize the importance of recognizing EBV in the differential diagnosis of lymphoproliferative disorders.
Main Methods:
- Literature review of EBV infections in immunodeficiency.
- Analysis of clinical phenotypes and diagnostic criteria.
- Case series or cohort study data on EBV-positive lymphoproliferative disorders.
Main Results:
- The primary clinical presentation is EBV genome-positive lymphoproliferative disorder.
- These disorders span a range from benign lymphoproliferation to aggressive malignant lymphoma.
- Severe or fatal infectious mononucleosis can occur, particularly in conditions like X-linked lymphoproliferative disease.
Conclusions:
- EBV poses a significant threat in immunocompromised hosts, leading to diverse lymphoproliferative conditions.
- Early diagnosis and management are crucial for improving outcomes in EBV-associated diseases.
- Understanding EBV pathogenesis in immunodeficiency is vital for developing targeted therapies.